| Identification | Back Directory | [Name]
Eliapixant | [CAS]
1948229-21-7 | [Synonyms]
Eliapixant
BAY 1817080
Benzamide, 3-(5-methyl-2-thiazolyl)-5-[[(3R)-tetrahydro-3-furanyl]oxy]-N-[(1R)-1-[2-(trifluoromethyl)-5-pyrimidinyl]ethyl]- | [Molecular Formula]
C22H21F3N4O3S | [MDL Number]
MFCD34470055 | [MOL File]
1948229-21-7.mol | [Molecular Weight]
478.49 |
| Hazard Information | Back Directory | [Uses]
Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough[1][2]. | [in vivo]
Eliapixant can be used for the research of coughs and diabetes complications[1]. | [IC 50]
P2X3 Receptor | [References]
[1] Spinaci A, et, al. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Front Pharmacol. 2021 Apr 13;12:653561. DOI:10.3389/fphar.2021.653561
[2] Morice A, et, al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240. DOI:10.1183/13993003.04240-2020 |
|
|